Fatigue in patients with cancer receiving outpatient chemotherapy: a prospective two-center study.
Cancer
Cancer-related fatigue
ESAS-r-J
Outpatient
Tiredness
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
17 Feb 2023
17 Feb 2023
Historique:
received:
20
10
2022
accepted:
06
02
2023
entrez:
21
2
2023
pubmed:
22
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
Cancer-related fatigue (CRF) is one of the most common symptoms in patients with cancer. However, CRF has not been sufficiently evaluated as it involves various factors. In this study, we evaluated fatigue in patients with cancer receiving chemotherapy in an outpatient setting. Patients with cancer receiving chemotherapy at the outpatient treatment center of Fukui University Hospital and Saitama Medical University Medical Center Outpatient Chemotherapy Center were included. The survey period was from March 2020 to June 2020. The frequency of occurrence, time, degree, and related factors were examined. All patients were asked to fill out the Edmonton Symptom Assessment System Revised Japanese version (ESAS-r-J) questionnaire, which is a self-administered rating scale, and patients with ESAS-r-J "Tiredness" scores of ≥ 3 were evaluated for factors related to tiredness, such as age, sex, weight, and laboratory parameters. A total of 608 patients were enrolled in this study. Fatigue after chemotherapy occurred in 71.0% of patients. ESAS-r-J "Tiredness" scores of ≥ 3 were observed in 20.4% of patients. The factors related to CRF were low hemoglobin level and high C-reactive protein level. Twenty percent of patients receiving cancer chemotherapy on an outpatient basis had moderate or severe CRF. Patients with anemia and inflammation are at increased risk of developing fatigue after cancer chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-related fatigue (CRF) is one of the most common symptoms in patients with cancer. However, CRF has not been sufficiently evaluated as it involves various factors. In this study, we evaluated fatigue in patients with cancer receiving chemotherapy in an outpatient setting.
METHODS
METHODS
Patients with cancer receiving chemotherapy at the outpatient treatment center of Fukui University Hospital and Saitama Medical University Medical Center Outpatient Chemotherapy Center were included. The survey period was from March 2020 to June 2020. The frequency of occurrence, time, degree, and related factors were examined. All patients were asked to fill out the Edmonton Symptom Assessment System Revised Japanese version (ESAS-r-J) questionnaire, which is a self-administered rating scale, and patients with ESAS-r-J "Tiredness" scores of ≥ 3 were evaluated for factors related to tiredness, such as age, sex, weight, and laboratory parameters.
RESULTS
RESULTS
A total of 608 patients were enrolled in this study. Fatigue after chemotherapy occurred in 71.0% of patients. ESAS-r-J "Tiredness" scores of ≥ 3 were observed in 20.4% of patients. The factors related to CRF were low hemoglobin level and high C-reactive protein level.
CONCLUSIONS
CONCLUSIONS
Twenty percent of patients receiving cancer chemotherapy on an outpatient basis had moderate or severe CRF. Patients with anemia and inflammation are at increased risk of developing fatigue after cancer chemotherapy.
Identifiants
pubmed: 36803913
doi: 10.1186/s40780-023-00275-0
pii: 10.1186/s40780-023-00275-0
pmc: PMC9936686
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Informations de copyright
© 2023. The Author(s).
Références
Int J Nurs Stud. 2020 Nov;111:103707
pubmed: 32920423
Eur J Cancer. 2002 Jan;38(1):27-43
pubmed: 11750837
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
Breast Cancer Res Treat. 2007 Oct;105(2):209-19
pubmed: 17203386
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Asian Pac J Cancer Prev. 2018 Apr 27;19(4):1047-1052
pubmed: 29699055
J Natl Compr Canc Netw. 2010 Aug;8(8):958-66
pubmed: 20870639
Phys Med Rehabil Clin N Am. 2017 Feb;28(1):65-88
pubmed: 27913001
Palliat Med. 2008 Jan;22(1):13-32
pubmed: 18216074
Breast. 2021 Apr;56:103-109
pubmed: 33668004
Cancer. 2005 Oct 15;104(8):1772-8
pubmed: 16116608
Support Care Cancer. 2020 Jun;28(6):2513-2522
pubmed: 32002618
Int J Oncol. 2002 Nov;21(5):1093-9
pubmed: 12370760
Oncologist. 1999;4(1):1-10
pubmed: 10337366
J Cancer Surviv. 2016 Feb;10(1):51-61
pubmed: 25876557
J Pain Symptom Manage. 2015 Nov;50(5):718-23
pubmed: 26169339
Gynecol Oncol. 2014 Mar;132(3):698-702
pubmed: 24472408
J Pain Symptom Manage. 1999 Oct;18(4):233-42
pubmed: 10534963
Oncology (Williston Park). 2000 Nov;14(11A):151-61
pubmed: 11195408
Gynecol Oncol. 2017 Sep;146(3):630-635
pubmed: 28552254
Front Pharmacol. 2021 Sep 07;12:658792
pubmed: 34557089
Ann Oncol. 2020 Jun;31(6):713-723
pubmed: 32173483
Ann Oncol. 2000 Aug;11(8):971-5
pubmed: 11038033
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247